Dr Reddy's Laboratories Ltd. recommended a final dividend of Rs 8 per share for a face value of Re 1 each for the financial year 2024–25.
The record date to determine the eligible shareholders for the dividend is set as July 10, according to exchange filing on Friday.
Dr Reddy's reported a 22% increase in consolidated net profit for the fourth quarter of fiscal 2025, surpassing analysts' expectations.
The pharmaceutical firm announced a net profit of Rs 1,593 crore for the quarter ended March 2025. This exceeded the Rs 1,459-crore forecast by analysts monitored by Bloomberg.
Shares of Dr Reddy's closed 0.69% higher at Rs 1,155.90 apiece on the NSE, compared to a 1.1% fall in the benchmark Nifty. The stock has fallen 1.66% in the last 12 months and 16.75% on a year-to-date basis.
Out of 38 analysts tracking the company, 15 have a 'buy' rating on the stock, 11 recommend 'hold' and 12 suggest 'sell', according to Bloomberg data. The average of 12-month analysts' price target implies a potential upside of 16.5%.
Essential Business Intelligence, Continuous LIVE TV, Sharp Market Insights, Practical Personal Finance Advice and Latest Stories — On NDTV Profit.
